Now showing items 1-1 of 1

    • EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors 

      Fillmore, Christine M.; Xu, Chunxiao; Desai, Pooja T.; Berry, Joanne M.; Rowbotham, Samuel P.; Lin, Yi-Jang; Zhang, Haikuo; Marquez, Victor E.; Hammerman, Peter S.; Wong, Kwok-Kin; Kim, Carla F. (2014)
      SUMMARY Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide1. Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC ...